- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
Intuitive Surgical: Great Technology, Tough Environment
-
Why I'm Closing Illumina for Now
-
Closing Update for July 2
-
Is IBB the Best Biotech ETF?
-
Thursday Options Update: MOT, AXP, JOSB & ILMN
-
Illumina Cuts Forecast on Stimulus Spend Delays
-
Illumina Boomerangs Up, Announces Genome Sequencing
-
Illumina's Great Day on Down Tape
-
Viking's Q109 Shows Conviction for Mastercard and Visa Duopoly
-
This Week's 20 'Babies with Bath Water' and 16 'Dogs with Fleas'
-
Pre-Market Report: Stocks on Course for Lower Start
-
Trying to Figure out What Illumina Is Telling Us
-
Illumina Sales Light Its Fire
-
Weekly Street Sentiment: Sometimes the Trend Is Not Your Friend
-
15 Long Ideas for Buying on Strength
-
Where Might Genentech Investors Redeploy $47B?
-
Illumina Dominating the Sequencing Market
-
Hedge Fund Portfolio Tracking: Andreas Halvorsen's Viking Global, Q4 2008
-
IBB: Newfound Stability Lures Biotech Investors
-
71 Stocks Leading the Nasdaq Higher
-
Wall Street Breakfast: Must-Know News
-
Healthcare Reform, M&A Likely to Focus on Preventative Medicine
-
Looking for the Biotech Breakout
-
New Emerging Diagnostics Index
-
Hedge Fund Tracking: John Griffin's Blue Ridge Capital, Q3 2008
-
10 Micro and Small Cap Healthcare Value Stocks Currently Under the Radar
-
Wednesday Options Update: WFC, PG, CVH, ISIL, ILMN, RMBS
-
Wall Street Breakfast: Must-Know News
-
Best and Worst Performing Stocks of the Current Bear Market
-
Three Biotech ETFs: A Way To Follow the 'Smart Money' into Healthcare
-
Biotech Bucks the Market Trend
-
Affymetrix Remains a Value Trap Until Its Results Improve
-
Illumini, Intuitive: This Healthcare Outperformance Brought to You by the Letter 'I'
-
Wall Street Breakfast: Must-Know News
-
Why I Bought Illumina
-
Big Biotech Booms But IBB Falls Flat
-
Does Valuation Matter?
-
Biotech in Review: Investments in China Drug Development
-
Illumina Sells 11 More Genome Analyzers to the Beijing Genomics Institute
-
Illumina Rises 20% on Settlement: Time to Cut Back
-
Illumina Rises 20% on Settlement: Time to Cut Back